Stifel lowered the firm’s price target on Revvity (RVTY) to $110 from $120 and keeps a Hold rating on the shares. Q2 performances in most business areas were inline with expectations, but new pressures in China for the ImmunoDx business have growth stepping down and pressure the overall outlook for the year, the analyst tells investors in a post-earnings note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity price target lowered to $115 from $120 at Raymond James
- Revvity’s Strategic Measures and Strong Software Performance Justify Buy Rating Despite FY25 Challenges
- Revvity’s Resilience: Strong Performance and Growth Opportunities Amidst Challenges
- Revvity, Inc. Earnings Call: Mixed Sentiment and Strategic Moves
- Revvity falls -9.0%